3,258 Shares in Hologic, Inc. (NASDAQ:HOLX) Purchased by RIA Advisory Group LLC

RIA Advisory Group LLC acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) during the 3rd quarter, Holdings Channel.com reports. The fund acquired 3,258 shares of the medical equipment provider’s stock, valued at approximately $265,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of HOLX. Price T Rowe Associates Inc. MD raised its position in shares of Hologic by 77.7% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock valued at $490,931,000 after acquiring an additional 2,753,016 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in shares of Hologic by 21.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock valued at $188,243,000 after buying an additional 450,190 shares during the last quarter. Black Creek Investment Management Inc. lifted its holdings in Hologic by 60.9% in the second quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after acquiring an additional 885,524 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in Hologic by 5.7% in the second quarter. Dimensional Fund Advisors LP now owns 2,326,992 shares of the medical equipment provider’s stock valued at $172,780,000 after acquiring an additional 124,739 shares during the period. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in shares of Hologic by 4.0% during the second quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,271,603 shares of the medical equipment provider’s stock valued at $168,666,000 after purchasing an additional 87,176 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on HOLX. Mizuho lowered their price objective on Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. Leerink Partners cut their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. JPMorgan Chase & Co. raised their price target on shares of Hologic from $92.00 to $94.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Stephens reiterated an “overweight” rating and set a $92.00 price objective on shares of Hologic in a research report on Tuesday, July 30th. Finally, Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Hologic in a research report on Tuesday, October 15th. Four investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $89.91.

Hologic Price Performance

Shares of HOLX traded up $1.06 during mid-day trading on Friday, hitting $78.60. The company’s stock had a trading volume of 1,834,908 shares, compared to its average volume of 1,593,948. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The firm has a 50-day moving average price of $80.71 and a 200 day moving average price of $78.23. Hologic, Inc. has a fifty-two week low of $67.59 and a fifty-two week high of $84.67. The stock has a market capitalization of $18.26 billion, a price-to-earnings ratio of 23.60, a PEG ratio of 2.50 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to analyst estimates of $978.25 million. During the same quarter in the previous year, the business posted $0.89 earnings per share. The firm’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, research analysts predict that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.